Cancer treatment systems maker BSD Medical Corp ([stock]BSDM[/stock]) recently showcased its MicroThermX Microwave Ablation system for soft tissue ablation (destruction) at its exhibition booth at the annual scientific meeting of the Society of Interventional Radiology (“SIR”) in Chicago.
SIR is the largest meeting in the U.S. for minimally invasive interventional radiology/oncology products with nearly 5,300 physicians, scientists and health professionals from across the globe having attended the event. BSD Medical used the SIR meeting to bolster the profile of its microwave ablation products and strengthen its association with international interventional oncologists and key opinion leaders.
BSD Medical introduced the innovative MicroThermX system in the U.S. in December 2010. Subsequently, the Utah-based company successfully rolled out its first MicroThermX system in Europe in January 2011.
BSD Medical has established a dedicated global distribution network for the MicroThermX products. The company is using the network of specialty distribution firms, which market products in the interventional radiology area.
All of BSD Medical’s U.S. distributors attended its exhibition booth at the SIR meet and helped customers to preview the ground-breaking MicroThermX system. Moreover, a large number of interventional oncologists scheduled a clinical evaluation of the device during and following the show.
The MicroThermX system leverages BSD Medical’s proprietary synchronous phased array technology to deliver precision-guided microwave energy to ablate soft tissues using a single-patient-use disposable antenna.
The minimally-invasive MicroThermX system has been developed to provide treatments as a stand-alone therapy and has applications in open surgical and percutaneous (via needle-puncture of the skin) ablation procedures.
As such, it can be used by both surgeons and interventional radiologists. The global market potential for soft tissue ablation has been estimated to exceed $ 2.3 billion, offering a significant opportunity for BSD Medical.
BSD Medical competes with established players like Boston Scientific ([stock]ANGO[/stock]) in the thermal ablation market. The company recently announced its second-quarter fiscal 2011 results with revenues sliding 26% year over year to roughly $ 444,000. However, net loss declined 19% to $ 1.55 million and lower costs more than offset the decline in sales.
ANGIODYNAMICS (ANGO): Free Stock Analysis Report
BOSTON SCIENTIF (BSX): Free Stock Analysis Report
Zacks Investment Research
Be the first to comment